Dose-finding Study in Platinum-Resistant Ovarian Cancer

NCT01653912 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Platinum-resistant Ovarian Cancer

Interventions

DRUG: GSK2110183 in combination with carboplatin and paclitaxel

Sponsor

Accenture